Cambridge biotech Thymmune wins $37m NIH grant for thymic cell therapies
The stem cell startup aims to bolster immune systems of patients born without a thymus or with poor thymic function by restoring T cell development.
The stem cell startup aims to bolster immune systems of patients born without a thymus or with poor thymic function by restoring T cell development.
What's Your Reaction?
